Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Mirum Pharmaceuticals stock | $24.02

Own Mirum Pharmaceuticals stock in just a few minutes.

Fact checked

Mirum Pharmaceuticals, Inc is a biotechnology business based in the US. Mirum Pharmaceuticals shares (MIRM) are listed on the NASDAQ and all prices are listed in US Dollars. Mirum Pharmaceuticals employs 67 staff and has a market cap (total outstanding shares value) of USD$613.9 million.

How to buy shares in Mirum Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Mirum Pharmaceuticals. Find the stock by name or ticker symbol: MIRM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Mirum Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$24.02, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Mirum Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Mirum Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Mirum Pharmaceuticals share price

Use our graph to track the performance of MIRM stocks over time.

Mirum Pharmaceuticals shares at a glance

Information last updated 2020-12-02.
Latest market closeUSD$24.02
52-week rangeUSD$8 - USD$28.31
50-day moving average USD$19.004
200-day moving average USD$19.9543
Wall St. target priceUSD$49.29
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-28.935

Buy Mirum Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Mirum Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Mirum Pharmaceuticals price performance over time

Historical closes compared with the close of $24.02 from 2020-12-09

1 week (2021-01-07) 25.17%
1 month (2020-12-17) 34.57%
3 months (2020-10-16) 17.69%
6 months (2020-07-16) 19.32%
1 year (2020-01-16) 11.31%
2 years (2019-01-13) N/A
3 years (2018-01-13) N/A
5 years (2016-01-13) N/A

Mirum Pharmaceuticals financials

Gross profit TTM USD$0
Return on assets TTM -35.82%
Return on equity TTM -63.06%
Profit margin 0%
Book value $6.479
Market capitalisation USD$613.9 million

TTM: trailing 12 months

Shorting Mirum Pharmaceuticals shares

There are currently 662,581 Mirum Pharmaceuticals shares held short by investors – that's known as Mirum Pharmaceuticals's "short interest". This figure is 1.8% up from 650,921 last month.

There are a few different ways that this level of interest in shorting Mirum Pharmaceuticals shares can be evaluated.

Mirum Pharmaceuticals's "short interest ratio" (SIR)

Mirum Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Mirum Pharmaceuticals shares currently shorted divided by the average quantity of Mirum Pharmaceuticals shares traded daily (recently around 57766.434176112). Mirum Pharmaceuticals's SIR currently stands at 11.47. In other words for every 100,000 Mirum Pharmaceuticals shares traded daily on the market, roughly 11470 shares are currently held short.

However Mirum Pharmaceuticals's short interest can also be evaluated against the total number of Mirum Pharmaceuticals shares, or, against the total number of tradable Mirum Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mirum Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Mirum Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0544% of the tradable shares (for every 100,000 tradable Mirum Pharmaceuticals shares, roughly 54 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Mirum Pharmaceuticals.

Find out more about how you can short Mirum Pharmaceuticals stock.

Mirum Pharmaceuticals share dividends

We're not expecting Mirum Pharmaceuticals to pay a dividend over the next 12 months.

Mirum Pharmaceuticals overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site